EXHIBIT 99.1
MISSISSAUGA, Ontario, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company"), a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today reported third quarter 2015 financial results. Results are reported in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).
Third Quarter Highlights
"During the third quarter we saw an increase in revenue sequentially versus the first half of 2015 and recently noted a number of operating achievements that position us well for a pickup in orders going forward," said Daryl Wilson, President and Chief Executive Officer. "E.ON inaugurated our 1.5 megawatt PEM energy storage system in Hamburg, Germany – our second reference site with this key customer and an important strategic milestone for Power-to-Gas installations. We also realized the start of commercial operations at Kolon Hydrogenics' initial one megawatt fuel cell power facility in South Korea. These events are being heralded by industry and government officials alike as groundbreaking in terms of our PEM hydrogen technology, which can be scaled for much greater energy applications. We look forward to additional orders from Kolon in the near future, once testing is complete, and Korea remains a very attractive market committed to using fuel cells for large-scale power generation – as recent activity attests.
"We delivered our first electrolysis units to Kurion during the quarter for the previously-announced purification of tritiated waste water. Subject to final pilot program results, this technology could represent substantial opportunities at Fukushima and other nuclear sites around the world. Overall, we expect to see a pickup in energy storage demand, fuel cell bus deliveries, and fueling station awards heading into 2016, along with the aforementioned Kolon orders. The Company remains well positioned for a broad array of hydrogen-based energy applications, our backlog is strong, and we are excited about the leading role we play across the hydrogen value chain."
Summary of Results for the Quarter Ended September 30, 2015
| Expected Revenue | |||||||
| Recognition | |||||||
| Orders | |||||||
| June 30, | Delivered/ | September | During | Beyond | |||
| 2015 | Orders | Revenue | 30, 2015 | next 12 | next 12 | ||
| backlog | Received | FX | Recognized | backlog | months | months | |
| OnSite Generation | $26.8 | $3.5 | $0.1 | $7.6 | $22.8 | $19.7 | $3.1 |
| Power Systems | 75.5 | 2.2 | 0.4 | 2.0 | 76.1 | 6.9 | 69.2 |
| Total | $102.3 | $5.7 | $0.5 | $9.6 | $98.9 | $26.6 | $72.3 |
Notes
Conference Call Details
Hydrogenics will hold a conference call at 10:00 a.m. EDT on November 10, 2015 to review the third quarter results. The telephone number for the conference call is (877) 307-1373 or, for international callers, (678) 224-7873. A live webcast of the call will also be available on the company's website, www.hydrogenics.com.
An archived copy of the conference call and webcast will be available on the company's website, www.hydrogenics.com, approximately six hours following the call.
About Hydrogenics
Hydrogenics Corporation is a world leader in engineering and building the technologies required to enable the acceleration of a global power shift. Headquartered in Mississauga, Ontario, Hydrogenics provides hydrogen generation, energy storage and hydrogen power modules to its customers and partners around the world. Hydrogenics has manufacturing sites in Germany, Belgium and Canada and service centers in Russia, Europe, the US and Canada.
Forward-looking Statements
This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, and under applicable Canadian securities law. These statements are based on management's current expectations and actual results may differ from these forward-looking statements due to numerous factors, including: our inability to increase our revenues or raise additional funding to continue operations, execute our business plan, or to grow our business; inability to address a slow return to economic growth, and its impact on our business, results of operations and consolidated financial condition; our limited operating history; inability to implement our business strategy; fluctuations in our quarterly results; failure to maintain our customer base that generates the majority of our revenues; currency fluctuations; failure to maintain sufficient insurance coverage; changes in value of our goodwill; failure of a significant market to develop for our products; failure of hydrogen being readily available on a cost-effective basis; changes in government policies and regulations; failure of uniform codes and standards for hydrogen fuelled vehicles and related infrastructure to develop; liability for environmental damages resulting from our research, development or manufacturing operations; failure to compete with other developers and manufacturers of products in our industry; failure to compete with developers and manufacturers of traditional and alternative technologies; failure to develop partnerships with original equipment manufacturers, governments, systems integrators and other third parties; inability to obtain sufficient materials and components for our products from suppliers; failure to manage expansion of our operations; failure to manage foreign sales and operations; failure to recruit, train and retain key management personnel; inability to integrate acquisitions; failure to develop adequate manufacturing processes and capabilities; failure to complete the development of commercially viable products; failure to produce cost-competitive products; failure or delay in field testing of our products; failure to produce products free of defects or errors; inability to adapt to technological advances or new codes and standards; failure to protect our intellectual property; our involvement in intellectual property litigation; exposure to product liability claims; failure to meet rules regarding passive foreign investment companies; actions of our significant and principal shareholders; dilution as a result of significant issuances of our common shares and preferred shares; inability of US investors to enforce US civil liability judgments against us; volatility of our common share price; and dilution as a result of the exercise of options. Readers should not place undue reliance on Hydrogenics' forward-looking statements. Investors are encouraged to review the section captioned "Risk Factors" in Hydrogenics' regulatory filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission for a more complete discussion of factors that could affect Hydrogenics' future performance. Furthermore, the forward-looking statements contained herein are made as of the date of this release, and Hydrogenics undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, unless otherwise required by law. The forward-looking statements contained in this release are expressly qualified by this.
| Reconciliation of Cash Operating Costs to Operating Costs and Adjusted EBITDA to Net Loss | ||||
| (in thousands of US dollars) | ||||
| (unaudited) | ||||
| Cash operating costs | ||||
| Three months ended | Nine months ended | |||
| September 30 | September 30 | |||
| 2015 | 2014 | 2015 | 2014 | |
| Selling, general and administrative expenses | $ 2,566 | $ 2,846 | $ 7,724 | $ 9,392 |
| Research and product development expenses | 1,045 | 1,160 | 3,106 | 2,991 |
| Total operating costs | $ 3,611 | $ 4,006 | $ 10,830 | $ 12,383 |
| Less: Depreciation of property, plant and equipment and intangibles | (95) | (81) | (272) | (235) |
| Less: Compensation costs indexed to share price | 174 | 120 | 408 | (473) |
| Less: Stock-based compensation losses | (163) | (170) | (457) | (462) |
| Cash operating costs | $ 3,527 | $ 3,875 | $ 10,509 | $ 11,213 |
| Adjusted EBITDA | ||||
| Three months ended | Nine months ended | |||
| September 30 | September 30 | |||
| 2015 | 2014 | 2015 | 2014 | |
| Net loss | $ (2,192) | $ (1,262) | $ (9,319) | $ (5,135) |
| Finance loss (income) | 682 | 323 | 2,785 | 977 |
| Depreciation of property, plant and equipment and intangible assets | 138 | 206 | 448 | 524 |
| Compensation indexed to share price | (174) | (120) | (408) | 473 |
| Stock-based compensation expense | 163 | 170 | 457 | 462 |
| Adjusted EBITDA | $ (1,383) | $ (683) | $ (6,037) | $ (2,699) |
| Hydrogenics Corporation | ||
| Condensed Interim Consolidated Balance Sheets | ||
| (in thousands of US dollars) | ||
| (unaudited) | ||
| September 30, | December 31, | |
| 2015 | 2014 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $ 6,930 | $ 6,572 |
| Restricted cash | 1,271 | 3,228 |
| Trade and other receivables | 11,906 | 12,900 |
| Inventories | 16,163 | 14,698 |
| Prepaid expenses | 621 | 747 |
| 36,891 | 38,145 | |
| Non-current assets | ||
| Restricted cash | 512 | 621 |
| Investment in joint venture | 1,883 | 2,150 |
| Property, plant and equipment | 2,770 | 1,873 |
| Intangible assets | 201 | 157 |
| Goodwill | 4,267 | 4,609 |
| 9,633 | 9,410 | |
| Total assets | $ 46,524 | $ 47,555 |
| Liabilities | ||
| Current Liabilities | ||
| Operating borrowings | $ 2,241 | $ -- |
| Trade and other payables | 9,960 | 13,156 |
| Derivative liability | 111 | -- |
| Warranty provisions | 1,814 | 1,392 |
| Deferred revenue | 9,746 | 6,771 |
| 23,872 | 21,319 | |
| Non-current liabilities | ||
| Other non-current liabilities | 10,270 | 3,464 |
| Non-current warranty provisions | 747 | 1,155 |
| Non-current deferred revenue | 5,082 | 6,141 |
| 16,099 | 10,760 | |
| Total liabilities | 39,971 | 32,079 |
| Equity | ||
| Share capital | 348,275 | 348,259 |
| Contributed surplus | 20,262 | 18,927 |
| Accumulated other comprehensive loss | (3,063) | (2,108) |
| Deficit | (358,921) | (349,602) |
| Total equity | 6,553 | 15,476 |
| Total equity and liabilities | $ 46,524 | $ 47,555 |
| Hydrogenics Corporation | ||||
| Consolidated Interim Statements of Operations and Comprehensive Loss | ||||
| (in thousands of US dollars, except share and per share amounts) | ||||
| (unaudited) | ||||
| Three months ended | Nine months ended | |||
| September 30, | September 30, | |||
| 2015 | 2014 | 2015 | 2014 | |
| Revenues | $ 9,644 | $ 11,093 | $ 24,543 | $ 29,875 |
| Cost of sales | 7,543 | 8,026 | 20,247 | 21,650 |
| Gross profit | 2,101 | 3,067 | 4,296 | 8,225 |
| Operating expenses | ||||
| Selling, general and administrative expenses | 2,566 | 2,846 | 7,724 | 9,392 |
| Research and product development expenses | 1,045 | 1,160 | 3,106 | 2,991 |
| 3,611 | 4,006 | 10,830 | 12,383 | |
| Loss from operations | (1,510) | (939) | (6,534) | (4,158) |
| Finance income (expenses) | ||||
| Interest expense, net | (446) | (105) | (942) | (369) |
| Foreign currency gains (losses), net | 382 | (156) | (381) | (365) |
| Loss from joint venture | (127) | (62) | (86) | (62) |
| Other finance losses, net | (491) | -- | (1,376) | (181) |
| Finance income (loss), net | (682) | (323) | (2,785) | (977) |
| Loss before income taxes | (2,192) | (1,262) | (9,319) | (5,135) |
| Income tax expense | -- | -- | -- | -- |
| Net loss for the period | (2,192) | (1,262) | (9,319) | (5,135) |
| Items that may be reclassified subsequently to net loss | ||||
| Exchange differences on translating foreign operations and joint venture | (79) | (985) | (955) | (1,052) |
| Comprehensive loss for the period | $ (2,271) | $ (2,247) | $ (10,274) | $ (6,187) |
| Net loss per share | ||||
| Basic and diluted | $ (0.22) | $ (0.13) | $ (0.92) | $ (0.54) |
| Hydrogenics Corporation | ||||
| Consolidated Interim Statements of Cash Flows | ||||
| (in thousands of US dollars) | ||||
| (unaudited) | ||||
| Three months ended | Nine months ended | |||
| September 30, | September 30, | |||
| 2015 | 2014 | 2015 | 2014 | |
| Cash and cash equivalents provided by (used in): | ||||
| Operating activities | ||||
| Net loss for the period | $ (2,192) | $ (1,262) | $ (9,319) | $ (5,135) |
| (Increase) decrease in restricted cash | 118 | (1,425) | 2,065 | (1,616) |
| Items not affecting cash: | ||||
| Amortization and depreciation | 138 | 206 | 448 | 524 |
| Other finance losses, net | 111 | -- | 111 | 181 |
| Unrealized foreign exchange losses (gains) | 227 | (230) | (29) | (140) |
| Unrealized loss on joint venture | 128 | 62 | 86 | 62 |
| Accreted non-cash and unpaid interest | 219 | 133 | 685 | 366 |
| Payment of post-retirement benefit liability | -- | (25) | -- | (70) |
| Portion of borrowings recorded as a reduction from research and development expenses | -- | -- | -- | (118) |
| Stock-based compensation | 163 | 170 | 457 | 462 |
| Stock based compensation – RSUs and DSUs | (174) | (120) | (408) | 473 |
| Warrant issuance | -- | -- | 885 | -- |
| Net change in non-cash working capital | 326 | (1,790) | (1,575) | (7,887) |
| Cash used in operating activities | (936) | (4,281) | (6,594) | (12,898) |
| Investing activities | ||||
| Investment in joint venture | -- | (947) | -- | (947) |
| Proceeds from disposals | -- | -- | -- | 9 |
| Purchase of property, plant and equipment | (674) | (20) | (1,553) | (545) |
| Receipt of IDF government funding | -- | -- | 118 | -- |
| Purchase of intangible assets | -- | (3) | (81) | (83) |
| Cash used in investing activities | (674) | (970) | (1,516) | (1,566) |
| Financing activities | ||||
| Repayment of repayable government contributions | (52) | (50) | (162) | (439) |
| Proceeds of borrowings, net of transaction costs | -- | -- | 6,866 | 854 |
| Proceeds of operating borrowings | 2,240 | -- | 6,062 | -- |
| Repayment of operating borrowings | (1,658) | -- | (3,809) | -- |
| Common shares issued | -- | 5 | 9 | 13,666 |
| Cash provided by financing activities | 530 | (45) | 8,966 | 14,081 |
| Effect of exchange rate fluctuations on cash and cash equivalents held | (6) | (663) | (498) | (740) |
| Increase (Decrease) in cash and cash equivalents during the period | (1,086) | (5,959) | 358 | (1,123) |
| Cash and cash equivalents - Beginning of period | 8,016 | 16,659 | 6,572 | 11,823 |
| Cash and cash equivalents - End of period | $ 6,930 | $ 10,700 | $ 6,930 | $ 10,700 |
CONTACT: Hydrogenics Contacts:
Bob Motz, Chief Financial Officer
Hydrogenics Corporation
(905) 361-3660
investors@hydrogenics.com
Chris Witty
Hydrogenics Investor Relations
(646) 438-9385
cwitty@darrowir.com